Fig_4.tif (4.89 MB)
ERK and AKT inhibitors reversed the hormetic effect of BER and restored the in vitro anticancer activity of chemotherapeutic agents (CTA).
figure
posted on 2015-09-30, 03:29 authored by Jiaolin Bao, Borong Huang, Lidi Zou, Shenghui Chen, Chao Zhang, Yulin Zhang, Meiwan Chen, Jian-Bo Wan, Huanxing Su, Yitao Wang, Chengwei HeB16-F10 cells were pretreated with 20 μM ERK inhibitor (ERKi) PD98059 (A, C, E, G) or 5 μM AKT inhibitor (AKTi) LY294002 (B, D, F, H) for 1 h. Cell viability was determined by WST-1 assay after 24 h treatment of 5 μM BER alone (A, B) or combined with CTA (C-H). Data were expressed as mean ± SD (n ≥ 3). *P < 0.05, **P < 0.01 compared to BER (A, B) or CTA (C-H) used alone. #P < 0.05, ##P < 0.01 compared to combination treatment of CTA and low dose BER.
